Investor Relations
TOP IR CONTENTS
The Latest Presentation Materials
Past Presentation MaterialsNXT007: Study Session on ISTH Presentation for Investors
Tatsuya Koyama,
NXT007 Lifecycle Leader
Upcoming Events(Upcoming Events (2 Most Recent))
Events & PresentationsAnnual Report 2024(Integrated Report)
Past Annual Report
What's New
-
Chugai Files for Additional Tumor-Agnostic Indication of Alecensa for ALK Fusion / Rearrangement Gene-Positive Solid Tumors Including Pediatric Patients
-
Eli Lilly’s Announcement Regarding Oral GLP-1 Orforglipron (Results of Phase III ACHIEVE-1 for Type 2 Diabetes Published in The New England Journal of Medicine)
-
Phase I/II Study in Hemophilia A Suggests NXT007 May Have the Potential to Provide Hemostatic Normalization
-
Roche Announces Global Phase III SUNMO Study Data for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (Combination Therapy with Lunsumio and Polivy)
-
Roche Announces New Safety Information of Elevidys for Non-Ambulatory Duchenne Muscular Dystrophy
External Evaluations
External Evaluations-
ESG Indices of Global Equities
DJSI is a leading ESG index developed by S&P Dow Jones Indices (USA). Companies are selected as a constituent annually based on an assessment of their economic, environmental and social sustainability.
-
ESG Indices Selected by GPIF
Chugai has been continuously included as a constituent stock of the all six ESG indices for Japanese equities since the initiation of ESG investment by the Government Pension Investment Fund (GPIF).
-
IR Activities
Chugai was ranked first for the first time in 2024 in the pharmaceutical sector for the “Selection of Excellent Companies in Corporate Disclosure by Securities Analysts” conducted by the Securities Analysts Association of Japan (SAAJ), a public interest incorporated association.
About Chugai
-
Company Outline
Company Profile, Business Process, Directors & Officers, Organization.
-
History of Chugai Pharmaceutical
Understanding Chugai’s history that fostered the business philosophy “Innovation all for the patients”
-
R&D
Easy-to-understand introduction of Chugai’s R&D structure, strategies and technologies.
